Evidence record · ER-MGF-MUSCLE-027
Does MGF or PEG-MGF increase muscle growth in people?
MGF or PEG-MGF increases muscle growth or recovery in people
MGF and PEG-MGF have no dependable human outcome evidence for increasing muscle growth, strength or recovery. Cell and animal experiments produce mechanistic signals, including conflicting in-vitro findings, but they do not establish human exposure, benefit or safety. FDA reports have also identified no human exposure data for PEG-MGF.
Claim boundary
What this verdict covers
The claim requires direct human measures of lean mass, strength, function or recovery after a precisely identified product. Cell proliferation and animal muscle responses are preclinical.
- Compound
- MGF and PEG-MGF
- Population
- Adults seeking muscle or recovery effects
- Outcome
- Lean mass, strength or recovery
- Record ID
- ER-MGF-MUSCLE-027
Evidence synthesis
What the research can support
Laboratory research examines splice variants and synthetic peptides under different conditions, with some results supporting and others questioning proposed activity. No controlled human development programme was identified for MGF or PEG-MGF muscle outcomes.
Why the confidence is very low
Sequence, pegylation and assay conditions materially affect interpretation. Human pharmacology, immunogenicity, product quality and adverse-event frequency remain unknown.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-MGF-MUSCLE-027 addresses one bounded question: Does MGF or PEG-MGF increase muscle growth in people?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Preclinical only, the verdict is Insufficient and confidence is Very low. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| MGF laboratory research | The paper reports mechanistic findings in experimental systems. | It is not human muscle-growth evidence. | 10 August 2026 |
| Critical review of the mechano-growth-factor hypothesis | The review separates IGF-I splice-variant expression from claims about an autonomous synthetic MGF peptide. | A mechanistic review cannot establish human muscle growth. | 10 August 2026 |
| FDA bulk-substance safety page | FDA reports no identified human exposure data and important safety gaps for PEG-MGF. | It does not test every vial. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on MGF and PEG-MGF for this claim?
The verdict is insufficient for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
Laboratory research examines splice variants and synthetic peptides under different conditions, with some results supporting and others questioning proposed activity. No controlled human development programme was identified for MGF or PEG-MGF muscle outcomes. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is MGF and PEG-MGF authorised in the UK for this use?
No UK marketing authorisation was identified for this use or for a medicine sold under this peptide name. The MHRA products database should be checked for the exact product and presentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Growth factors and related substances are prohibited at all times under the WADA S2 category. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion. Read the cited source and stated scope together before relying on it.
What could change this verdict?
A regulated first-in-human programme followed by independently replicated trials measuring muscle and functional outcomes with complete safety reporting. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation